Amyloidogenesis of SARS-CoV-2 delta plus and omicron variants receptor-binding domain (RBD): impact of SUMO fusion tag

被引:0
|
作者
Zargan, Sadegh [1 ]
Jalili, Hasan [1 ]
Dabirmanesh, Bahareh [2 ]
Mesdaghinia, Saba [2 ]
Khajeh, Khosro [2 ]
机构
[1] Univ Tehran, Fac New Sci & Technol, Dept Life Sci Engn, Tehran, Iran
[2] Tarbiat Modares Univ, Fac Biol Sci, Dept Biochem, Tehran, Iran
关键词
Amyloidogenic properties; Delta plus; Omicron; RBD; SARS-CoV-2; AMYLOID FIBRIL; INFRARED-SPECTROSCOPY; THIOFLAVIN-T; PROTEIN; TECHNOLOGY; MUTATIONS;
D O I
10.1007/s10529-024-03525-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
PurposeThe RBD of SARS-CoV-2 mediates viral entry into host cells by binding to the host receptor ACE2. SARS-CoV-2 infection is linked to various health issues resembling amyloid-related problems, persuading us to investigate the amyloidogenicity of the SARS-CoV-2 spike RBD.MethodsThe FoldAmyloid program was used to assess the amyloidogenic propensities in the RBD of Delta Plus and RBD of the Omicron variant, with and without the SUMO tag. After the expression of RBDs, purification, and dialysis steps were performed, subsequently the ThT assay, FTIR, and TEM were employed to check the RBD ability to form fibrils.ResultsThe ThT assay, TEM, and FTIR revealed the ability of RBD to self-assemble into beta-sheet-rich aggregates (48.4% beta-sheet content). Additionally, the presence of the SUMO tag reduced the formation of RBD amyloid-like fibrils. The amyloidogenic potential of Omicron RBD was higher than Delta Plus, according to both in silico and experimental analyses.ConclusionsThe SARS-CoV-2 RBD can assemble itself by forming aggregates containing amyloid-like fibrils and the presence of a SUMO tag can significantly decrease the formation of RBD amyloid-like fibrils. In silico analysis suggested that variation in the ThT fluorescence intensity of amyloid accumulations in the two SARS-CoV-2 strains arises from specific mutations in their RBD regions.
引用
收藏
页码:1037 / 1048
页数:12
相关论文
共 50 条
  • [1] The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex
    Peka, Mykyta
    Balatsky, Viktor
    FUTURE VIROLOGY, 2023, 18 (04) : 225 - 242
  • [2] Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant
    Singh, Vishakha
    Choudhary, Shweta
    Bhutkar, Mandar
    Nehul, Sanketkumar
    Ali, Sabika
    Singla, Jitin
    Kumar, Pravindra
    Tomar, Shailly
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 290
  • [3] Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity
    Kodchakorn, Kanchanok
    Kongtawelert, Prachya
    PLOS ONE, 2022, 17 (11):
  • [4] Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain
    Miller, Nathaniel L.
    Clark, Thomas
    Raman, Rahul
    Sasisekharan, Ram
    CELL REPORTS MEDICINE, 2022, 3 (02)
  • [5] Exploring SARS-CoV-2 Delta variant spike protein receptor-binding domain (RBD) as a target for tanshinones and antimalarials
    Coghi, Paolo
    Yun, Xiao Yun
    Ng, Jerome P. L.
    Law, Betty Yuan Kwan
    Memo, Maurizio
    Gianoncelli, Alessandra
    Wong, Vincent Kam Wai
    Ribaudo, Giovanni
    NATURAL PRODUCT RESEARCH, 2022, 36 (23) : 6150 - 6155
  • [6] Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
    Mehalko, Jennifer
    Drew, Matthew
    Snead, Kelly
    Denson, John-Paul
    Wall, Vanessa
    Taylor, Troy
    Sadtler, Kaitlyn
    Messing, Simon
    Gillette, William
    Esposito, Dominic
    PROTEIN EXPRESSION AND PURIFICATION, 2021, 179
  • [7] Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
    Kaewchim, Kanasap
    Glab-ampai, Kittirat
    Mahasongkram, Kodchakorn
    Saenlom, Thanatsaran
    Thepsawat, Watayagorn
    Chulanetra, Monrat
    Choowongkomon, Kiattawee
    Sookrung, Nitat
    Chaicumpa, Wanpen
    VIRUSES-BASEL, 2023, 15 (06):
  • [8] A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
    Wanbo Tai
    Xiujuan Zhang
    Aleksandra Drelich
    Juan Shi
    Jason C. Hsu
    Larry Luchsinger
    Christopher D. Hillyer
    Chien-Te K. Tseng
    Shibo Jiang
    Lanying Du
    Cell Research, 2020, 30 : 932 - 935
  • [9] A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
    Tai, Wanbo
    Zhang, Xiujuan
    Drelich, Aleksandra
    Shi, Juan
    Hsu, Jason C.
    Luchsinger, Larry
    Hillyer, Christopher D.
    Tseng, Chien-Te K.
    Jiang, Shibo
    Du, Lanying
    CELL RESEARCH, 2020, 30 (10) : 932 - 935
  • [10] Redirecting a Broad-Spectrum Nanobody Against the Receptor-Binding Domain of SARS-CoV-2 to Target Omicron Variants
    Intasurat, Kwanpet
    Submunkongtawee, Nonth
    Longsompurana, Phoomintara
    Thaiprayoon, Apisitt
    Kasemsukwimol, Warisara
    Sirimanakul, Suwitchaya
    Boonsilp, Siriphan
    Seetaha, Supaphron
    Choowongkomon, Kiattawee
    Waraho-Zhmayev, Dujduan
    APPLIED SCIENCES-BASEL, 2024, 14 (22):